Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 413611-93-5 Chemical Structure| 413611-93-5

Structure of 10074-G5
CAS No.: 413611-93-5

Chemical Structure| 413611-93-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

10074-G5 is a c-Myc Max interaction inhibitor.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 10074-G5

CAS No. :413611-93-5
Formula : C18H12N4O3
M.W : 332.31
SMILES Code : O=[N+](C1=CC=C(NC2=CC=CC=C2C3=CC=CC=C3)C4=NON=C41)[O-]
MDL No. :MFCD00576774
InChI Key :KMJPYSQOCBYMCF-UHFFFAOYSA-N
Pubchem ID :2836600

Safety of 10074-G5

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H315-H319-H335
Precautionary Statements:P261-P301+P310-P305+P351+P338
Class:6.1
UN#:2811
Packing Group:

Related Pathways of 10074-G5

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Myc-Cap cells 25 μM 24 h Evaluate the effect of Myc inhibitors on GFAT1 expression and protein glycosylation. Results showed that 10074-G5 significantly upregulated GFAT1 expression and increased protein glycosylation levels. Theranostics. 2023 Jan 1;13(2):578-595.
RM1 cells 25 μM 24 h Evaluate the effect of Myc inhibitors on GFAT1 expression and protein glycosylation. Results showed that 10074-G5 significantly upregulated GFAT1 expression and increased protein glycosylation levels. Theranostics. 2023 Jan 1;13(2):578-595.
PC3 cells 25 μM 24 h Evaluate the effect of Myc inhibitors on GFAT1 expression and protein glycosylation. Results showed that 10074-G5 significantly upregulated GFAT1 expression and increased protein glycosylation levels. Theranostics. 2023 Jan 1;13(2):578-595.
monomeric Aβ40 200 μM measure heat changes upon 10074-G5 binding to Aβ40 using isothermal titration calorimetry, indicating the interaction is largely entropic Sci Adv. 2020 Nov 4;6(45):eabb5924.
monomeric Aβ42 20 μM characterize the binding of 10074-G5 to monomeric Aβ42, finding Aβ42 remains disordered in the bound form Sci Adv. 2020 Nov 4;6(45):eabb5924.
HL-60 human promyelocytic leukemic cells 13.5 ± 2.1 μM 72 h To evaluate the growth inhibitory potency of 10074-G5 against HL-60 cells, results showed that 10074-G5 effectively inhibited cell growth J Pharmacol Exp Ther. 2010 Dec;335(3):715-27.
Daudi Burkitt’s lymphoma cells 15.6 ± 1.5 μM 72 h To evaluate the growth inhibitory potency of 10074-G5 against Daudi cells, results showed that 10074-G5 effectively inhibited cell growth J Pharmacol Exp Ther. 2010 Dec;335(3):715-27.
human renal proximal tubule cells (RPTCs) 30 μM 3 h Pre-treatment with 10074-G5 completely restored FEN-stimulated cAMP accumulation in uRPTCs to normal levels. Hypertension. 2013 May;61(5):1021-7.
human renal proximal tubule cells (RPTCs) 30 μM 24 h 10074-G5 completely blocked the PMA-mediated increase in GRK4 expression, restoring GRK4 expression to basal levels. Hypertension. 2013 May;61(5):1021-7.
ALK+ALCL cells 5 μM 24 h Inhibits MYC-MAX heterodimerization and their DNA binding, significantly abrogating H2O2-induced RU/RR conversion BMC Cancer. 2018 Apr 2;18(1):361.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice RM-1 prostate cancer model Intravenous injection 10 mg/kg Once every 3 days, total 5 times Evaluate the antitumor activity of 10074-DON-loaded PS nanocarrier in vivo. Results showed that PS/10074-DON significantly inhibited tumor growth and improved the tumor immune microenvironment. Theranostics. 2023 Jan 1;13(2):578-595.
C.B-17 SCID mice Daudi Burkitt’s lymphoma xenografts Intravenously 20 mg/kg Once daily for 5 days To evaluate the antitumor efficacy of 10074-G5 in vivo, results showed that 10074-G5 did not significantly inhibit the growth of Daudi xenografts J Pharmacol Exp Ther. 2010 Dec;335(3):715-27.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.01mL

0.60mL

0.30mL

15.05mL

3.01mL

1.50mL

30.09mL

6.02mL

3.01mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories